Let’s Hope Drug Companies Win Price Controls War – Pacific Research Institute

Let’s Hope Drug Companies Win Price Controls War

Health pexels artem podrez 8532824

The House Committee on Oversight and Accountability met last week for a hearing on the Inflation Reduction Act’s first year. As one of the witnesses pointed out, the law’s implementation — particularly its drug pricing reforms — have already run afoul of some of our government’s most basic norms of transparency and accountability.

The IRA gives federal officials the authority to dictate what Medicare pays for certain medicines — a scheme intended to reduce the government’s drug bill. Late last month, the Department of Health and Human Services announced the first 10 drugs subject to the law’s price controls, which include the blood thinners Eliquis and Xarelto.

These price controls represent an unprecedented intervention in the market for prescription drugs that is likely to carry serious negative consequences for patients.

Read the full article at Newsmax

Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.

Scroll to Top